Search - tctmd.com

Displaying 241 - 260 of 263

Sort: Relevancy | Date

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Daily News

FDA Classifies Latest HeartWare VAD Recalls as Class I

Michael O'Riordan

October 24, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Daily News

AHA 提供他汀类药物和心血管药物药物相互作用指导

Michael O'Riordan

October 18, 2016

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

研究称缺血性心肌病的患者可以受益于心肌卸负荷

Michael O'Riordan

October 17, 2016

News Daily News

Según un Estudio Los Pacientes con Cardiomiopatía Isquémica se Benefician de Descargas Miocárdicas

Michael O'Riordan

October 17, 2016

News Daily News

Ischemic Cardiomyopathy Patients Can Benefit From Myocardial Unloading, Study Suggests

Michael O'Riordan

October 17, 2016

News Daily News

欧洲大型分析显示当前 NSAID 使用与心力衰竭的风险增加相关

Michael O'Riordan

September 30, 2016

News Daily News

Según un Extenso Análisis Europeo el Uso Actual de FAINE se asocia a un Mayor Riesgo de Insuficiencia Cardíaca

Michael O'Riordan

September 30, 2016

News Daily News

Current NSAID Use Linked to Increased Risk of Heart Failure, Large European Analysis Shows

Michael O'Riordan

September 30, 2016

News Conference News ESC 2016

ICDs Do Not Reduce Mortality in Patients With HF Not Caused by Coronary Artery Disease: DANISH

Michael O'Riordan

August 28, 2016

News Daily News

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

Michael O'Riordan

August 24, 2016

News Daily News

FDA Warns of Class I Recall for HeartWare VAD Batteries

Michael O'Riordan

June 29, 2016

News Daily News

Abbott Buys St. Jude Medical for $25 Billion, Gaining More Muscle in Cardiovascular Device Arena

Michael O'Riordan

April 29, 2016

News Conference News ACC 2016

‘Enhanced’ Multicellular Stem Cell Therapy Improves Clinical Outcomes in Heart Failure: ixCELL-DCM Study

Michael O'Riordan

April 04, 2016

News Daily News

越来越多证据显示以肠促胰岛素类降糖药不会增加心衰风险

Michael O'Riordan

March 25, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Daily News

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

Michael O'Riordan

March 25, 2016

News Daily News

比较分析表明无心衰患者使用 ACE 抑制剂和 ARB 类药物效果相当

Michael O'Riordan

January 19, 2016

Advertisement

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

FDA Classifies Latest HeartWare VAD Recalls as Class I

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

AHA 提供他汀类药物和心血管药物药物相互作用指导

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

研究称缺血性心肌病的患者可以受益于心肌卸负荷

Según un Estudio Los Pacientes con Cardiomiopatía Isquémica se Benefician de Descargas Miocárdicas

Ischemic Cardiomyopathy Patients Can Benefit From Myocardial Unloading, Study Suggests

欧洲大型分析显示当前 NSAID 使用与心力衰竭的风险增加相关

Según un Extenso Análisis Europeo el Uso Actual de FAINE se asocia a un Mayor Riesgo de Insuficiencia Cardíaca

Current NSAID Use Linked to Increased Risk of Heart Failure, Large European Analysis Shows

ICDs Do Not Reduce Mortality in Patients With HF Not Caused by Coronary Artery Disease: DANISH

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

FDA Warns of Class I Recall for HeartWare VAD Batteries

Abbott Buys St. Jude Medical for $25 Billion, Gaining More Muscle in Cardiovascular Device Arena

‘Enhanced’ Multicellular Stem Cell Therapy Improves Clinical Outcomes in Heart Failure: ixCELL-DCM Study

越来越多证据显示以肠促胰岛素类降糖药不会增加心衰风险

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina

比较分析表明无心衰患者使用 ACE 抑制剂和 ARB 类药物效果相当

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content